Repligen (NASDAQ:RGEN) Now Covered by Analysts at Evercore ISI

Equities researchers at Evercore ISI started coverage on shares of Repligen (NASDAQ:RGEN) in a research note issued on Tuesday, MarketBeat.com reports. The brokerage set an “in-line” rating and a $155.00 price target on the biotechnology company’s stock. Evercore ISI’s price objective suggests a potential upside of 1.43% from the company’s current price.

A number of other equities research analysts have also recently weighed in on RGEN. JPMorgan Chase & Co. lifted their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. TD Cowen initiated coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. Royal Bank of Canada upped their target price on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research report on Friday, February 21st. Canaccord Genuity Group lifted their price target on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Finally, StockNews.com lowered Repligen from a “hold” rating to a “sell” rating in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Repligen presently has an average rating of “Hold” and a consensus target price of $178.64.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $152.81 on Tuesday. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $200.23. The business has a 50 day moving average price of $157.16 and a two-hundred day moving average price of $148.53. The firm has a market cap of $8.56 billion, a PE ratio of -299.63, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The business had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Sell-side analysts expect that Repligen will post 1.72 earnings per share for the current fiscal year.

Institutional Trading of Repligen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Atria Investments Inc raised its holdings in shares of Repligen by 67.9% during the third quarter. Atria Investments Inc now owns 3,202 shares of the biotechnology company’s stock valued at $477,000 after acquiring an additional 1,295 shares during the period. CIBC Asset Management Inc purchased a new position in shares of Repligen during the third quarter valued at $242,000. Natixis Advisors LLC raised its position in Repligen by 53.6% during the third quarter. Natixis Advisors LLC now owns 33,625 shares of the biotechnology company’s stock valued at $5,004,000 after buying an additional 11,731 shares during the period. Quest Partners LLC purchased a new stake in Repligen in the 3rd quarter worth about $166,000. Finally, LMR Partners LLP acquired a new stake in Repligen during the 3rd quarter worth about $3,597,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.